(Corrects headline and bullets to show company gets approval for clinical trial to test Favipiravir for pneumonia caused by novel coronavirus)
Feb 17 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd :
* RECEIVES APPROVAL TO MANUFACTURE FAVIPIRAVIR FOR NEW AND RECURRING INFLUENZA IN ADULTS
* SAYS IT RECEIVES APPROVAL TO START CLINICAL TRIALS FOR USE OF FAVIPIRAVIR TO TREAT PNEUMONIA CAUSED BY NEW CORONAVIRUS Source text in Chinese: bit.ly/2SKKE3S Further company coverage: (Reporting by Hong Kong newsroom; Editing by Tom Hogue)
Our Standards: The Thomson Reuters Trust Principles.